Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-4729 injection approved for clinical trials.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, the company and its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (referred to as "NMPA") for HRS-4729 injection solution, and will start clinical trials soon. HRS-4729 injection solution is a peptide drug independently developed by the company, which is a triple agonist of glucagon-like peptide-1 receptor (GLP-1R)/glucose-dependent insulinotropic peptide receptor (GIPR)/glucagon receptor (GCGR). Compared with the dual targets of GLP-1R/GIPR, the triple receptor agonist increases GCGR activation activity by regulating sugar and fat metabolism and suppressing appetite in the body, promoting energy expenditure, fatty acid oxidation, lipid breakdown, and thus better achieving weight loss and reduction of liver fat.